Rutherford-based Cancer Genetics Inc., a provider of medicines for oncology, announced Tuesday it has appointed Michael McCartney as its new chief commercial officer, effective immediately.
“We are excited to welcome Michael to Cancer Genetics as we execute on our plans to transform the business to accelerate the path to profitability by expanding revenues in our biopharma and discovery businesses in the near term,” said John A. Roberts, CEO of Cancer Genetics. “Michael’s leadership and expertise in sales and marketing management and commercial strategy development will be instrumental in driving sustainable growth for our company.”
McCartney will be responsible for the company’s commercial strategy and business development initiatives.
McCartney has more than 20 years of experience in the life sciences, diagnostic and lab services industry. Before Cancer Genetics, he was CEO of SciKon Innovation Inc. Before that, he was chief operating officer at SciKon. Earlier in his career, he held positions at BioAgilytix Labs, Roche, Siemens and Abbott.
“The team at Cancer Genetics’ is committed to leveraging its expertise in developing advanced assays and tests, especially in the immuno-oncology arena, to continue transforming cancer diagnosis and treatment, and empowering our biopharma partners’ development efforts,” McCartney said. “I am pleased to be a part of the team and look forward to building and executing commercial and business initiatives focused on bringing important new tests and services to biopharma and biotech companies that enhance the development of drugs designed to improve patient outcomes.”
